ADJUVANT THERAPIES AND MARKERS OF POST-SURGICAL MINIMAL RESIDUAL DISEASE by Gianni Bonadonna (Editor), Georges Mathe (Editor), S. E. Salmon (Editor) ( 9783642813221 )

Item Details

Title:

ADJUVANT THERAPIES AND MARKERS OF POST-SURGICAL MINIMAL RESIDUAL DISEASE
MARKERS AND GENERAL PROBLEMS OF CANCER ADJUVANT THERAPIES

By:

Gianni Bonadonna (Editor), Georges Mathe (Editor), S. E. Salmon (Editor)

Format:

Paperback

List price:	£99.99
We currently do not stock this item, please contact the publisher directly for further information.

ISBN 10:

3642813224

ISBN 13:

9783642813221

Publisher:

SPRINGER-VERLAG BERLIN AND HEIDELBERG GMBH & CO. KG

Pub. date:

8 December, 2011

Edition:

Softcover reprint of the original 1st ed. 1979

Series:

Recent Results in Cancer Research 67

Pages:

154

Description:

1978 Annual Plenary Meeting of the European Organization for Treatment of Cancer, Paris, June 1978

Synopsis:

P. Denoix and G. Mathe Approximately 70% of cancer patients relapse after surgery before the 5th year and, in most cases, for example in breast carcinoma, they relapse still later up to the 20th year. For some considerable time, the strategy of cancer treatment has been limited to the sophistication of surgery-radiotherapy combinations that maximally decreased the incidence of local and regional relapses in sites that were within their reach. Today, the practice of clinical oncology is unthinkable without the active participation of the medical oncologist. He is the "third man" of the clinical oncology team, and he has recently focused attention on the fact that most relapses arise from distant metastases due to the proliferation of cells seeded there after having left the primary tumor site at the time of operation and, hence, are inaccessible to any form oflocal and/or regional treatment. On this evidence, medical oncologists have proposed the application of medical treatments for disseminated minimal residual disease (MRD). They have two available means: chemother- apy and immunotherapy.Medical oncologists in general can be divided into three groups: chemotherapists, immunotherapists, and chemoimmunotherapists. The pure chemotherapists, who had already cured some malignant neoplasias such as Hodgkin's disease, acute lymphoid leukemia, placental choriocarcinoma, and Wilms' tumor, thought they might have the means of attacking the residual disease of common cancers.

Illustrations:

6 black & white illustrations, biography

Publication:

Germany

Imprint:

Springer-Verlag Berlin and Heidelberg GmbH & Co. K

Returns:

Returnable

Some other items by this author:

ADJUVANT THERAPIES AND MARKERS OF POST-SURGICAL MINIMAL RESIDUAL DISEASE II (PB)

ADJUVANT THERAPIES OF CANCER (PB)

ADVANCES IN THE TREATMENT OF ACUTE (BLASTIC) LEUKEMIAS